Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HOB Biotech GroupSHSE:688656 -2.73%78 Net Margin % is 0.22% as of Mar. 2026, which is 98% below its 10-year median of 13.80. GuruFocus rates SHSE:688656 with a GF Score™ of 78/100 and a GF Value™ of ¥89.36 (Modestly Undervalued). The stock has 8 warning signs investors should review. Among 816 Medical Devices & Instruments companies, HOB Biotech Group ranks better than 59.56% on this metric.
The historical rank and industry rank for HOB Biotech Group's Net Margin % or its related term are showing as below:
SHSE:688656'
s Net Margin % Range Over the Past 10 Years
Min: 3.88 Med: 13.8 Max: 27.13
Current: 5.44
SHSE:688656's Net Margin % is ranked better than 59.56% of 816
companies
in the Medical Devices & Instruments industry
Industry Median: 2.11
vs SHSE:688656: 5.44
HOB Biotech Group (SHSE:688656) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
HOB Biotech Group Net Margin % Related Terms
HOB Biotech Group Net Margin % Historical Data
* Premium members only.
The historical data trend for HOB Biotech Group's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688656 vs ABT, SYK, MDT: Net Margin % Comparison
For the Medical Devices subindustry, HOB Biotech Group's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HOB Biotech Group Net Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, HOB Biotech Group's Net Margin % distribution charts can be found below:
* The bar in red indicates where HOB Biotech Group's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HOB Biotech Group (SHSE:688656) has a Net Margin % of 0.22% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on HOB Biotech Group and its competitors. This is 98% below median its historical median of 13.80. Over the past decade, HOB Biotech Group's Net Margin % has ranged from 3.88 to 27.13. According to the industry distribution chart, HOB Biotech Group ranks #330 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 40.4%.
Is HOB Biotech Group's Net Margin % too high?
HOB Biotech Group's current Net Margin % of 0.22% is 98% below median its 10-year median of 13.80. Over the past 10 years, this metric has ranged from a low of 3.88 to a high of 27.13. The Medical Devices & Instruments industry median Net Margin % is 2.11. HOB Biotech Group's value of 0.22% is 89.6% below this industry median. Based on the distribution chart, HOB Biotech Group ranks #330 out of 816 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, HOB Biotech Group has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does HOB Biotech Group's Net Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, HOB Biotech Group ranks #330 out of 816 companies for Net Margin %. This puts HOB Biotech Group in the upper half of its industry. The industry median Net Margin % is 2.11. HOB Biotech Group's value of 0.22% is 89.6% below this benchmark. Historically, HOB Biotech Group's own Net Margin % has ranged from 3.88 to 27.13 over the past decade. While the company's 10-year median is 13.80 vs. the industry median of 2.11, HOB Biotech Group has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Devices & Instruments company?
The median Net Margin % among Medical Devices & Instruments companies is 2.11, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. HOB Biotech Group's current Net Margin % of 0.22% is 89.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on HOB Biotech Group and its competitors. For the Medical Devices & Instruments industry, the median Net Margin % is 2.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. HOB Biotech Group's current Net Margin % is 0.22%, which is 98% below median its own 10-year median of 13.80. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HOB Biotech Group stock overvalued right now?
Based on GuruFocus' analysis, HOB Biotech Group (SHSE:688656) is currently considered Modestly Undervalued. The stock's GF Value™ is ¥89.36, compared to a current price of ¥79.04 — trading 11.5% below its estimated fair value. The current Net Margin % is 0.22%, which is 98% below median its 10-year median of 13.80 and 89.6% below the Medical Devices & Instruments industry median of 2.11. HOB Biotech Group's overall GF Score™ is 78/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For HOB Biotech Group (SHSE:688656), the current Net Margin % is 0.22% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HOB Biotech Group (SHSE:688656) Overvalued in 2026?
Based on GuruFocus' analysis, HOB Biotech Group stock appears to be undervalued.
The current stock price of ¥79.04 is trading 11.5% below its estimated GF Value™ of ¥89.36.
GuruFocus considers HOB Biotech Group to be Modestly Undervalued.
Key valuation signals for SHSE:688656:
Net Margin %: 0.22% (98% below median its 10-year median of 13.80)
GF Value™: ¥89.36 vs. price of ¥79.04 (11.5% below fair value)
Industry Position: 89.6% below the Medical Devices & Instruments median (#330 of 816)
No single metric tells the full story. See the SHSE:688656 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HOB Biotech Group Corp Ltd is an in vitro diagnostic company. The firm is specialized in providing diagnostic tools to laboratories and hospitals for the improvement of allergy and autoimmune disease patient care.
78GF Score
Get the complete analysis for SHSE:688656
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688656 has been successfully added to your 
